The Claim
Based on allometric scaling from animal models, achieving cytoprotective and anti-inflammatory effects of melatonin in humans likely requires daily doses of 100 to 200 mg, and the current clinical trial dosage of 2 to 10 mg may explain inconsistent cardiovascular therapeutic outcomes.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Animal studies suggest that humans might need 100 to 200 milligrams of melatonin daily to get its protective and anti-inflammatory benefits, which is much higher than the 2 to 10 milligrams usually tested in heart studies. This big difference in dosage might be why past heart research hasn't shown clear results.
See the scientific wording
Allometric calculations derived from animal models suggest that achieving cytoprotective and anti-inflammatory effects of melatonin in humans may require daily doses of 100 to 200 mg, substantially exceeding the 2 to 10 mg typically utilized in current clinical trials. This dosage discrepancy is proposed as a potential reason for the inconsistent therapeutic outcomes observed in human cardiovascular studies.
What the research says
1 studyStudy: Chronobiotic and cytoprotective activity of melatonin in the cardiovascular system. Doses matter
The study agrees that animal research suggests humans need much higher doses of melatonin to protect the heart, which explains why current low-dose trials often fail to show clear benefits.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.